You may not know that Taiwan produces nearly 1,607 metric tons of hazardous medical waste in the form of discarded sharps every year. These injections are enough to circle the equator of the earth more than once and cover 89 101 Buildings. That’s not all. Including hospital personnel costs and *** treatment costs, medical waste consumes a lot of social resources. In order to reduce the burden of medical costs, it has become an inevitable trend. It is also a major issue facing countries around the world, and a new technology The establishment is effectively changing this urgent situation.
Yinhua Biotech Pharmaceutical Co., Ltd. has the patented technology of "OralPAS? (injectable drugs into oral drugs)". This technology has been successfully approved by the US Food and Drug Administration (FDA) to enter the human body on September 9, 2011. clinical trials. The original word "Oral" means oral, and when paired with "pas", the combination of the two words means that this technology can be "penetrated and absorbed through oral administration". This technology platform will start to drive global biotechnology towards a new direction of "green medical care".
The "OralPAS? (Injectable Drugs Converted to Oral Drugs)" technology is specifically targeted at "difficult to absorb" drugs to develop drug delivery systems. Inhua has also targeted cancer drugs, immune preparations and other special drugs for development. Invar Biotech Pharmaceutical Co., Ltd. will announce this new technology that is unique in the world - treating cancer as a chronic disease. This patented technology platform can not only be applied to the research and development of new formulations of drugs with difficult formulations, but also obtain subsequent launch and marketing , and relevant drug delivery technology can be applied to the development of new drugs and the design of new drug dosage forms. If the research on anti-cancer drugs is successful, patients will not need to go to the hospital for chemotherapy, but can instead take oral methods to maintain good blood concentrations, and Treating cancer as a chronic disease can also reduce medical costs and risks. In the future, it can create a value of up to 30 million U.S. dollars in single drug development authorizations. This technology and FDA approval have successfully attracted international major pharmaceutical companies. In the future, There is definitely a chance to develop into the light of Taiwan’s biotechnology. Subscribe to the Healthy Love Live video and audio channel to read health knowledge more easily. Join and pay attention to your health every day! LINE＠ ID: @：/cancer/article/729/Oral medicines replace injections and create green medical treatment Keywords: OralPAS, injection medicines, oral medicines, Inva Biotech